Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Intervacc ABFRA:2E9 +1.30%63 Cash Ratio is 3.90 as of Jun. 2026, which is 1% below its 10-year median of 3.93. GuruFocus rates FRA:2E9 with a GF Score™ of 63/100 and a GF Value™ of €0.08. The stock has 1 warning sign investors should review. Among 1,383 Biotechnology companies, Intervacc AB ranks better than 56.98% on this metric.
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Intervacc AB Cash Ratio Related Terms
Intervacc AB Cash Ratio Historical Data
* Premium members only.
The historical data trend for Intervacc AB's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:2E9 vs VRTX, REGN, MRNA: Cash Ratio Comparison
For the Biotechnology subindustry, Intervacc AB's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Intervacc AB Cash Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Intervacc AB's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Intervacc AB's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Intervacc AB (FRA:2E9) has a Cash Ratio of 3.90 as of Jun. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Intervacc AB and its competitors. This is near median its historical median of 3.93. Over the past decade, Intervacc AB's Cash Ratio has ranged from 0.53 to 11.74. According to the industry distribution chart, Intervacc AB ranks #595 out of 1383 companies in the Biotechnology industry, placing it in the top 43%.
Is Intervacc AB's Cash Ratio too high?
Intervacc AB's current Cash Ratio of 3.90 is near median its 10-year median of 3.93. Over the past 10 years, this metric has ranged from a low of 0.53 to a high of 11.74. The Biotechnology industry median Cash Ratio is 2.94. Intervacc AB's value of 3.90 is 32.7% above this industry median. Based on the distribution chart, Intervacc AB ranks #595 out of 1383 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Intervacc AB has a GF Score™ of 63/100, reflecting its overall financial health beyond just this single metric.
How does Intervacc AB's Cash Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Intervacc AB ranks #595 out of 1383 companies for Cash Ratio. This puts Intervacc AB in the upper half of its industry. The industry median Cash Ratio is 2.94. Intervacc AB's value of 3.90 is 32.7% above this benchmark. Historically, Intervacc AB's own Cash Ratio has ranged from 0.53 to 11.74 over the past decade. While the company's 10-year median is 3.93 vs. the industry median of 2.94, Intervacc AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Biotechnology company?
The median Cash Ratio among Biotechnology companies is 2.94, based on 1,383 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Intervacc AB's current Cash Ratio of 3.90 is 32.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Intervacc AB and its competitors. For the Biotechnology industry, the median Cash Ratio is 2.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Intervacc AB's current Cash Ratio is 3.90, which is near median its own 10-year median of 3.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Intervacc AB stock overvalued right now?
Intervacc AB (FRA:2E9) has a current Cash Ratio of 3.90. The stock's GF Value™ is €0.08, compared to a current price of €0.08 — trading 2.4% below its estimated fair value. The current Cash Ratio is 3.90, which is near median its 10-year median of 3.93 and 32.7% above the Biotechnology industry median of 2.94. Intervacc AB's overall GF Score™ is 63/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Intervacc AB (FRA:2E9), the current Cash Ratio is 3.90 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Intervacc AB (FRA:2E9) Overvalued in 2026?
Based on GuruFocus' analysis, Intervacc AB stock appears to be undervalued.
The current stock price of €0.08 is trading 2.4% below its estimated GF Value™ of €0.08.
Key valuation signals for FRA:2E9:
Cash Ratio: 3.90 (near median its 10-year median of 3.93)
GF Value™: €0.08 vs. price of €0.08 (2.4% below fair value)
Industry Position: 32.7% above the Biotechnology median (#595 of 1383)
No single metric tells the full story. See the FRA:2E9 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Intervacc AB is a biotechnology company. It develops new vaccines based on recombinant proteins to meet the increasing need for effective vaccines in animal health care. The company through its subsidiary focuses on diagnostics in the Swedish animal health market and offers bacteriological and mycological analyses on the Swedish market.
63GF Score
Get the complete analysis for FRA:2E9
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:2E9 has been successfully added to your 
